WO2006095029A3 - Di-polymer protein conjugates and processes for their preparation - Google Patents

Di-polymer protein conjugates and processes for their preparation Download PDF

Info

Publication number
WO2006095029A3
WO2006095029A3 PCT/EP2006/060671 EP2006060671W WO2006095029A3 WO 2006095029 A3 WO2006095029 A3 WO 2006095029A3 EP 2006060671 W EP2006060671 W EP 2006060671W WO 2006095029 A3 WO2006095029 A3 WO 2006095029A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
preparation
protein conjugates
polymer protein
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/060671
Other languages
French (fr)
Other versions
WO2006095029A2 (en
Inventor
Michael Bavand
Horst Blasey
Dietmar Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siegfried AG
Original Assignee
Siegfried AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siegfried AG filed Critical Siegfried AG
Priority to JP2008500216A priority Critical patent/JP2008535793A/en
Priority to EP06725029A priority patent/EP1869079A2/en
Publication of WO2006095029A2 publication Critical patent/WO2006095029A2/en
Publication of WO2006095029A3 publication Critical patent/WO2006095029A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention refers to di-polymer protein conjugates and processes for their preparation. Further, the present invention refers to the use of such di-polymer protein conjugate, especially di-pegylated protein conjugate, for the manufacture of a medicament for the treatment of disorders.
PCT/EP2006/060671 2005-03-11 2006-03-13 Di-polymer protein conjugates and processes for their preparation Ceased WO2006095029A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008500216A JP2008535793A (en) 2005-03-11 2006-03-13 Dipolymer / protein conjugate and preparation method thereof
EP06725029A EP1869079A2 (en) 2005-03-11 2006-03-13 Di-polymer protein conjugates and processes for their preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/002632 WO2006094530A1 (en) 2005-03-11 2005-03-11 Di-polymer protein conjugates and processes for their preparation
EPPCT/EP2005/002632 2005-03-11

Publications (2)

Publication Number Publication Date
WO2006095029A2 WO2006095029A2 (en) 2006-09-14
WO2006095029A3 true WO2006095029A3 (en) 2006-11-30

Family

ID=35276216

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/002632 Ceased WO2006094530A1 (en) 2005-03-11 2005-03-11 Di-polymer protein conjugates and processes for their preparation
PCT/EP2006/060671 Ceased WO2006095029A2 (en) 2005-03-11 2006-03-13 Di-polymer protein conjugates and processes for their preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002632 Ceased WO2006094530A1 (en) 2005-03-11 2005-03-11 Di-polymer protein conjugates and processes for their preparation

Country Status (2)

Country Link
JP (1) JP2008535793A (en)
WO (2) WO2006094530A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP2066336B1 (en) 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Use of pegylated il-10 to treat cancer
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
US8530417B2 (en) 2007-12-29 2013-09-10 Biosteed Gene Expression Tech Co. Ltd. Y-shaped polyethylene glycol modified G-CSF, the preparation and use thereof
CN101981057B (en) 2008-03-31 2013-07-24 旭化成纤维株式会社 Cellulose derivative fine particles, dispersions of the same, dispersions thereof, and diagnostic drugs
US9840546B2 (en) * 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
MX344559B (en) * 2008-04-29 2016-12-20 Ascendis Pharma As Pegylated recombinant human growth hormone compounds.
AR072850A1 (en) * 2008-07-31 2010-09-22 Pharmaessentia Corp PEPTIDO-POLYMER CONJUGATES
AU2009308909A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-PEGylated granulocyte colony stimulating factor
ES2655364T3 (en) * 2008-12-17 2018-02-19 Merck Sharp & Dohme Corp. Production of mono- and dipegilated IL-10 and its uses
MX2015014438A (en) 2013-04-18 2016-05-18 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders.
EP3010527B1 (en) * 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN120242030A (en) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 to treat diseases and conditions
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (en) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 Methods for using interleukin-10 to treat diseases and disorders
CN110702895B (en) * 2018-12-28 2024-03-01 上海长岛生物技术有限公司 D-dimer detection reagents and methods, reagent preparation methods and polyethylene glycol applications
CN115463258B (en) * 2021-09-13 2023-09-08 熹微(苏州)生物医药科技有限公司 Bionic cornea and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1998025965A2 (en) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides and compounds that bind to the thrombopoietin receptor
WO2000021574A2 (en) * 1998-10-14 2000-04-20 Amgen Inc. Site-directed dual pegylation of proteins
WO2001051510A2 (en) * 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
WO2001076640A2 (en) * 2000-04-07 2001-10-18 Amgen Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20030143596A1 (en) * 2001-11-07 2003-07-31 Shearwater Corporation Branched polymers and their conjugates
WO2004028568A1 (en) * 2002-09-27 2004-04-08 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
WO2004083242A1 (en) * 2003-03-21 2004-09-30 Hanmi Pharm. Co. Ltd. Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1998025965A2 (en) * 1996-12-11 1998-06-18 Glaxo Group Limited Peptides and compounds that bind to the thrombopoietin receptor
WO2000021574A2 (en) * 1998-10-14 2000-04-20 Amgen Inc. Site-directed dual pegylation of proteins
WO2001051510A2 (en) * 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
WO2001076640A2 (en) * 2000-04-07 2001-10-18 Amgen Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20030143596A1 (en) * 2001-11-07 2003-07-31 Shearwater Corporation Branched polymers and their conjugates
WO2004028568A1 (en) * 2002-09-27 2004-04-08 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
WO2004083242A1 (en) * 2003-03-21 2004-09-30 Hanmi Pharm. Co. Ltd. Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAILON P ET AL: "Polyethylene glycol-conjugated pharmaceutical proteins", PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY 1998 UNITED KINGDOM, vol. 1, no. 8, 1998, pages 352 - 356, XP002354431, ISSN: 1461-5347 *
CHAMOW S M ET AL: "MODIFICATION OF CD4 IMMUNOADHESIN WITH MONOMETHOXYPOLY(ETHYLENE GLYCOL) ALDEHYDE VIA REDUCTIVE ALKYLATION", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 5, no. 2, 1 March 1994 (1994-03-01), pages 133 - 140, XP000434384, ISSN: 1043-1802 *
GRACE MICHAEL J ET AL: "Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 8, 25 February 2005 (2005-02-25), pages 6327 - 6336, XP002391026, ISSN: 0021-9258 *
LEE K C ET AL: "Preparation and characterization of polyethylene-glycol-modified salmon calcitonins.", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY. MAY 1999, vol. 4, no. 2, May 1999 (1999-05-01), pages 269 - 275, XP009069735, ISSN: 1083-7450 *
ROBERTS M J ET AL: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 459 - 476, XP002293146, ISSN: 0169-409X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon

Also Published As

Publication number Publication date
JP2008535793A (en) 2008-09-04
WO2006095029A2 (en) 2006-09-14
WO2006094530A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2008006535A3 (en) Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP2450360A3 (en) (S)-N-Methylnaltrexone
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
WO2005115421A8 (en) Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2010058926A3 (en) Pharmaceutical composition containing ginger extract or shogaol
WO2009059755A3 (en) Novel neurturin conjugates for pharmaceutical use
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
WO2009053628A3 (en) Novel compounds, preparation and uses thereof
WO2007104768A3 (en) Di-polymer protein conjugates and processes for their preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008500216

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006725029

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006725029

Country of ref document: EP